VP's at GSK and AstraZeneca preent at Cancer Drugs R&D conference
December 28, 2007 (PRLEAP.COM) Health NewsMONROVIA, CA – Robert Copeland, VP of Biology, Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline to give keynote presentation at 5th Cancer Drugs R&D conference on February 21-22, 2008 in Phoenix.
Dr. Copeland will present on mechanism-driven approaches to molecularly targeted cancer drug discovery.
Oncology drug discovery at GlaxoSmithKline is focused on molecularly targeted therapeutics for the treatment of cancer and for cancer supportive care indications. A guiding principle of the company’s approach is that a detailed, mechanistic understanding of pathobiology and of drug action – at the molecular, cellular and organismal level – is essential for effective drug discovery. Towards this end GlaxoSmithKline has built a discovery organization that encompasses robust biochemical, cellular biological and in vivo pharmacological interrogation of drug candidates. Examples of the application of these approaches to several cancer drug-seeking efforts will be presented at the conference.
Jeffrey Hanke, Vice President of Cancer Research at AstraZeneca, will also give a keynote presentation.
Dr. Hanke will present on developing new therapeutics for the treatment of cancer. He will discuss challenges and opportunities within the field of cancer drugs.
AstraZeneca’s cancer discovery research operations are considered a top priority within the company. AstraZeneca also focuses on novel approaches to cancer prevention and therapy. The company is optimistic about future compounds and drugs for the treatment of cancer.
The 5th Cancer Drugs Research & Development conference features presentations on the successes and setbacks of modern cancer drugs, new drug compounds and future drugs for the treatment and prevention of cancer, cancer drug development in clinical trials and new drug delivery methods. For more information, visit www.gtcbio.com.
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, firstname.lastname@example.org